Myovant Sciences announced Sunday it formed a special committee of independent directors to assess Sumitovant Biopharma’s offer to acquire the company, and ultimately, turned the offer down.
Swedish geneticist Svante Paabo won the 2022 Nobel Prize in Physiology or Medicine on Monday for discoveries that underpin our understanding of how modern day humans evolved from extinct ancestors.
Moderna Inc. has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.
Around two-thirds of adults in the United States do not plan to get updated COVID-19 booster shots soon, according to a survey conducted by the Kaiser Family Foundation (KFF), a health policy nonprofit organization.
Intercept Pharmaceuticals Inc. said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.
As it gears up to launch several new products in the coming months, Moderna has created a new leadership role and onboarded an industry veteran, the company announced Thursday.
Two struggling Boston-based gene therapy companies – Solid Biosciences and AavantiBio – announced Friday they are merging to develop a portfolio of neuromuscular and cardiac programs, initially focusing on a lead candidate to treat Duchenne muscular dystrophy.
Clear evidence this week that Eisai and Biogen’s drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward a tantalizing goal – preventing dementia even before symptoms start.
Ordaōs and NonExomics announced a research pact to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.
Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.
